The immune-related pseudogenes signature can assess survival and immune checkpoint inhibitor response of patients with anti-PD-1 and anti-CTLA4 therapy, potentially enabling more personalized and precise tumor immunotherapy in the future. Here, CTLA4 is linked to neoplasm.